Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Muncie, IN
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Hickory, NC
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Middletown, OH
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Bend, OR
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated:  8/8/2016
mi
from
Buenos Aires,
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
Status: Enrolling
Updated: 8/8/2016
mi
from
Buenos Aires,
Click here to add this to my saved trials
FoundationOne™ Test Registry Study
A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test
Status: Enrolling
Updated:  8/8/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
FoundationOne™ Test Registry Study
A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test
Status: Enrolling
Updated: 8/8/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
La Jolla, CA
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Washington,
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Louisville, KY
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
New York, NY
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
Clinical Research Facility
mi
from
Cleveland, OH
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  8/8/2016
mi
from
Wien,
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 8/8/2016
mi
from
Wien,
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
Keck Hospital of USC
mi
from
Los Angeles, CA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
Keck Hospital of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
Lac & Usc Medical Center
mi
from
Los Angeles, CA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
University of Colorado Denver CTO (CTRC)
mi
from
Aurora, CO
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
University of Colorado Denver CTO (CTRC)
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
University of Colorado Hospital
mi
from
Aurora, CO
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
Swedish Medical Center
mi
from
Seattle, WA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
University of Washington Medical Center
mi
from
Seattle, WA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  8/8/2016
USC/Norris Comprehensive Cancer Center /Investigational Drug Services
mi
from
Los Angeles, CA
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 8/8/2016
USC/Norris Comprehensive Cancer Center /Investigational Drug Services
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
Immediate Vaginal Reconstruction Following Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
Immediate Vaginal Reconstruction Following Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan-Kettering Cancer Center
mi
from
Commack, NY
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan-Kettering Cancer Center
mi
from
Commack, NY
Click here to add this to my saved trials
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated:  8/9/2016
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Enrolling
Updated: 8/9/2016
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  8/9/2016
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 8/9/2016
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
UC San Diego Medical Center
mi
from
La Jolla, CA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
UC San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Facey Medical Foundation
mi
from
Mission Hills, CA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Facey Medical Foundation
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Medical Research Center of Conneticut
mi
from
Hamden, CT
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Medical Research Center of Conneticut
mi
from
Hamden, CT
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Gastroenterology Associates
mi
from
Baton Rouge, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Gastroenterology Associates
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Delta Research Partners, LLC
mi
from
Monroe, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Delta Research Partners, LLC
mi
from
Monroe, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
HealthEast Midway Clinic
mi
from
St. Paul, MN
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
HealthEast Midway Clinic
mi
from
St. Paul, MN
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Click here to add this to my saved trials